{"id":"W2891356992","doi":"10.1016/j.euf.2018.08.022","title":"ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Astellas Pharma; Physicians' Services Incorporated Foundation; Ipsen Biopharmaceuticals; Genentech; Bayer; Celgene; Meso Scale Diagnostics; Novartis; Amgen","keywords":"Medicine; Prostate cancer; CYP17A1; Androgen deprivation therapy; Castration; Androgen receptor; Oncology; Internal medicine; Dual (grammatical number); Orchiectomy; Urology; Cancer; Hormone","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000899174,0.0008820826,0.001165718,0.0005166669,0.0002605265,0.0007788697,0.0007273898,0.0006953017,0.002385647],"category_scores_gemma":[0.0005719142,0.0003960349,0.001137688,0.0004398974,0.0006237746,0.0005630833,0.0003167707,0.002828629,0.0004999366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005686764,"about_ca_system_score_gemma":0.0009351599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001425436,"about_ca_topic_score_gemma":0.005489009,"domain_scores_codex":[0.9997949,0.00006666067,0.00001006827,0.00002609344,0.00003712179,0.00006526357],"domain_scores_gemma":[0.9997461,0.00006006069,0.00004053996,0.00002388172,0.00001597513,0.0001134376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1514276,0.04496185,0.01131134,0.001867227,0.002112622,0.000565376,0.0005697451,0.007590392,0.1007668,0.0007367328,0.009648546,0.6684418],"study_design_scores_gemma":[0.3676307,0.5045543,0.05208148,0.0002603099,0.002159134,0.001969166,0.0003908885,0.006302117,0.03823553,0.0009836655,0.02524759,0.0001852851],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843971,0.009771896,0.001130544,0.0006614222,0.0001355692,0.0006032143,0.000821567,0.0002334847,0.002245223],"genre_scores_gemma":[0.9795277,0.009238436,0.003405574,0.001105991,0.0001042747,0.0004455543,0.002365825,0.00007944068,0.00372727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002385647,"threshold_uncertainty_score":0.007980764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02384032539890793,"score_gpt":0.295741604209543,"score_spread":0.2719012788106351,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}